Skip to content

MDMA: all studies

Page 15 of 345: studies 141 to 150 of 3,446, newest first. Back to the MDMA overview

Research

Intermittent MDMA Attenuates Ovariectomy-induced Bone Loss via a Gut Microbiota-Bone Axis.

Clinical Psychopharmacology and Neuroscience November 30, 2025 Xiayun Wan, Akifumi Eguchi, Rumi Murayama et al. 5 citations

3,4-Methylenedioxymethamphetamine (MDMA) is widely used recreationally but also modulates serotonergic signaling in the gut, potentially influencing the microbiota. Because low bone mineral density (BMD) is common in depression and other psychiatric disorders, we tested whether repeated, intermittent MDMA attenuates BMD loss in ovariectomized (OVX) mice. OVX mice received MDMA (10 mg/kg) three...

DOI: 10.9758/cpn.25.1309 (opens in new tab) Full text (opens in new tab) MDMA Bone mineral density Gut microbiota Metabolites

A meta-analytic analysis of the acute effects of MDMA on empathy and emotion recognition in humans

Scientific Reports November 29, 2025 Leehe Peled-Avron, Jacob S. Aday, Madeline M. Pantoni et al. 1 citation

3,4-methylenedioxymethamphetamine (MDMA) is an amphetamine derivative known as an "entactogen," influencing emotional and social processing. Phase III clinical trials of MDMA-assisted psychotherapy for post-traumatic stress disorder have reported promising results, and MDMA-assisted therapy is currently under regulatory review. However, the precise mechanisms underlying positive treatment...

MDMA-assisted therapy for major depressive disorder: A seven-month follow-up proof of principle trial

Journal of Psychiatric Research November 27, 2025 Tor-Morten Kvam, Ivar W Goksøyr, Joanna Róg et al. 3 citations

BACKGROUND: Major depressive disorder (MDD) is a leading cause of global disability, and current treatments often fail to provide sustained effectiveness. MDMA-assisted therapy (MDMA-AT) is a promising treatment for MDD. However, the long-term effects are not known. OBJECTIVES: To examine the long-term effects of MDMA-AT for MDD. METHODS: Twelve participants with MDD and an ongoing moderate to...

DOI: 10.1016/j.jpsychires.2025.11.030 (opens in new tab) Major depressive disorder Depression economics Proof of concept Depressive symptoms +4

3,4-Methylenedioxymethamphetamine (MDMA) does not induce robust psychomotor activation and 50-kHz ultrasonic vocalisations in tryptophan hydroxylase 2 (Tph2)-deficient rats lacking serotonin in the central nervous system.

British Journal of Pharmacology November 23, 2025 Tianhua Wang, Rainer K.W. Schwarting, Markus Wöhr 1 citation

3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a psychostimulant with entactogenic properties and known to induce arousal and euphoria. As an amphetamine derivate, MDMA acts on the monoamine systems in the brain and stimulates release of dopamine (DA), noradrenaline (NA) and serotonin (5-HT), yet their individual contributions in driving arousal and euphoria remain...

DOI: 10.1111/bph.70226 (opens in new tab) Full text (opens in new tab) Locomotor activity Psychostimulant Tryptophan hydroxylase 2 Ecstasy effects: ecstasy +13

Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: A systematic review and meta-analysis.

Journal of Psychopharmacology November 19, 2025 Hillary Ung, Gemma Mckeon, Zorica Jokovic et al. 1 citation

Little is known about whether 3,4-methylenedioxy-N-methamphetamine (MDMA) neurocognitive side effects improve with sustained abstinence. This study aimed to systematically review and synthesise the existing literature on the long-term neurocognitive side effects of recreational MDMA use after a minimum of 6 months of abstinence. We searched relevant databases utilising terms related to (1) MDMA...

DOI: 10.1177/02698811251389559 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxy-n-methamphetamine MDMA Neurocognition Abstinence effects Cognitive impairment +1

"New kid on the block"-MDDM as a new ingredient in Ecstasy tablets.

Journal of Forensic Sciences November 18, 2025 Bogumiła Byrska, Karolina Masier, Roman Stanaszek

Ecstasy tablets are commonly associated with 3,4-methylenedioxy-methamphetamine (MDMA), but they often contain diverse psychoactive substances, including new psychoactive substances (NPS), which pose significant risks to users due to unknown composition and effects. This study analyzed 150 Ecstasy tablets seized in Poland between 2020 and 2021, shaped as "Stormtrooper" heads, to identify their...

Comparative Efficacy of Psilocybin and MDMA in PTSD Treatment: A Systematic Review of Long-Term Outcomes

Berkeley Scientific Journal November 13, 2025 Presley Aspen

Highly stressful events can lead to post-traumatic stress disorder (PTSD)-a significant public health concern which existing treatments (e.g., psychotherapy and traditional medications) have shown marginal efficacy for.Psychedelics-alternatively called hallucinogens-are psychoactive substances that cause perception, mood, and cognitive changes.Because they are known for their impact on neuron...

A TERAPIA ASSISTIDA POR MDMA NO TRATAMENTO DE TRANSTORNO DE ESTRESSE PÓS-TRAUMÁTICO (TEPT) GRAVE E REFRATÁRIO

Asclepius International Journal of Scientific Health Science November 12, 2025 Carla Karoline de Oliveira Salotti, Mariana Espindola Fregulia, Renato Boy de Oliveira et al.

Introdução: Uma parcela substancial de pacientes com Transtorno de Estresse Pós-Traumático (TEPT), estimada entre 30% e 50%, não alcança remissão com as terapias padrão-ouro (ISRS e psicoterapia). Este cenário de refratariedade constitui um desafio clínico significativo. A terapia assistida por 3,4-metilenodioximetanfetamina (MDMA) emerge como uma intervenção com potencial disruptivo para esta...

MDMA como facilitador terapêutico: o impacto na reintegração de experiências traumáticas

DELOS Desarrollo Local Sostenible November 12, 2025 Maria Eduarda Mesquita Gonsalves, Beatriz Moreira Brazil, Maurício Cupello Peixoto

O Transtorno de Estresse Pós-Traumático (TEPT) é uma condição mental que pode surgir após experiências traumáticas, afetando a qualidade de vida dos indivíduos. O tratamento convencional envolve psicoterapia e farmacoterapia, contudo, nem sempre apresenta resultados satisfatórios. Nesse cenário, a psicoterapia assistida por 3,4-metilenodioximetanfetamina (MDMA) tem emergido como alternativa...

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

European Neuropsychopharmacology November 7, 2025 Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al. 12 citations

Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in...

DOI: 10.1016/j.euroneuro.2025.09.011 (opens in new tab) Psychedelic therapy MDMA Therapy Psychedelic medicine Entheogenic therapy +12